CWA Asset Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

CWA Asset Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Sell	857 -269	-24%	-$119K	0.01%	525
2026 Q1	$503K	Sell	1,126 -2,663	-70%	-$1.24M	0.02%	488
2025 Q4	$1.72M	Buy	3,789 +320	+9%	+$138K	0.06%	265
2025 Q3	$1.36M	Sell	3,469 -2,805	-45%	-$1.17M	0.05%	304
2025 Q2	$2.79M	Buy	6,274 +69	+1%	+$31.8K	0.12%	165
2025 Q1	$3.01M	Buy	6,205 +81	+1%	+$37.7K	0.14%	140
2024 Q4	$2.47M	Sell	6,124 -183	-3%	-$84.8K	0.12%	147
2024 Q3	$2.93M	Buy	+6,307	New	+$3.03M	0.16%	123
2024 Q1	$3.58M	Buy	8,576 +6,789	+380%	+$2.87M	0.22%	100
2023 Q4	$727K	Buy	1,787 +308	+21%	+$114K	0.05%	203
2023 Q3	$514K	Buy	1,479 +276	+23%	+$96.5K	0.04%	218
2023 Q2	$423K	Buy	1,203 +206	+21%	+$69.4K	0.03%	238
2023 Q1	$314K	Buy	+997	New	+$299K	0.02%	253

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

CWA Asset Management Group's VRTX Position: Q2 2026 in Review

CWA Asset Management Group reduced its Vertex Pharmaceuticals (VRTX) stake by 24% in Q2 2026, selling an estimated $119K and leaving 857 shares worth $426K. The position accounts for 0.01% of the portfolio, ranked #525.

CWA Asset Management Group first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.58M in Q1 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

CWA Asset Management Group held 857 shares of Vertex Pharmaceuticals worth $426K as of Q2 2026.
CWA Asset Management Group sold 269 Vertex Pharmaceuticals shares in Q2 2026, an estimated $119K.
Vertex Pharmaceuticals made up 0.01% of CWA Asset Management Group's portfolio in Q2 2026, its #525 holding.
CWA Asset Management Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
CWA Asset Management Group's Vertex Pharmaceuticals position peaked at $3.58M in Q1 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CWA Asset Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.